A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

被引：0
|
作者：
Siu, LL
Takimoto, CH
Awada, A
Moore, MJ
Piccart, M
Poulin-Costello, M
Lathia, C
Petrenciuc, O
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[3] Inst Jules Bordet, B-1000 Brussels, Belgium
[4] Bayer Inc, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3059
引用
收藏
页码：209S / 209S
页数：1
相关论文
共 50 条
  • [31] Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours
    Hirte, H
    Moore, M
    Hotte, S
    Oza, A
    Siu, L
    Harris, H
    MacLean, M
    Petrenciuc, O
    Fiander, W
    Lathia, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S55 - S55
  • [32] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
    A Awada
    A Hendlisz
    T Gil
    S Bartholomeus
    M Mano
    D de Valeriola
    D Strumberg
    E Brendel
    C G Haase
    B Schwartz
    M Piccart
    British Journal of Cancer, 2005, 92 : 1855 - 1861
  • [33] BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience.
    Ahmad, T
    Marais, R
    Pyle, L
    James, M
    Schwartz, B
    Gore, M
    Eisen, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 711S - 711S
  • [34] First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment
    Maroto-Rey, P.
    Bellmunt, J.
    Trigo, J. M.
    Guillem, V.
    Lopez-Martin, J. A.
    Carles, J.
    Anton-Torres, A.
    Urruticoechea, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Phase I trial of gemcitabine in patients with advanced pancreatic cancer
    Okada, S
    Ueno, H
    Okusaka, T
    Ikeda, M
    Furuse, J
    Maru, Y
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (01) : 7 - 12
  • [36] A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
    David B. Zhen
    Kent A. Griffith
    Joshua M. Ruch
    Kevin Camphausen
    Jason E. Savage
    Edward J. Kim
    Vaibhav Sahai
    Diane M. Simeone
    Mark M. Zalupski
    Investigational New Drugs, 2016, 34 : 733 - 739
  • [37] A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
    Zhen, David B.
    Griffith, Kent A.
    Ruch, Joshua M.
    Camphausen, Kevin
    Savage, Jason E.
    Kim, Edward J.
    Sahai, Vaibhav
    Simeone, Diane M.
    Zalupski, Mark M.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (06) : 733 - 739
  • [38] A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors
    Doss, H. H.
    Jones, S. F.
    Infante, J. R.
    Spigel, D. R.
    Willcutt, N.
    Lamar, R.
    Barton, J.
    Keegan, M.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the PMH phase II consortium.
    Welch, S
    Hirte, H
    Schilder, R
    Townsley, C
    Tinker, L
    Pond, G
    Afinec, A
    Wright, J
    Oza, A
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9059S - 9059S
  • [40] Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    Strumberg, D
    Richly, H
    Hilger, RA
    Schleucher, N
    Korfee, S
    Tewes, M
    Faghih, M
    Brendel, E
    Voliotis, D
    Haase, CG
    Schwartz, B
    Awada, A
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) : 965 - 972
12345